Study Overview: This clinical study, called CATALINA-2, is testing a new medicine, TORL-1-23, for women with advanced ovarian cancer that does not respond to platinum-based treatments. The study is in Phase 2, which means it's checking the safety (if it's safe to use) and effectiveness (if it works well) of the drug.
Complex Terms:
- **Platinum-resistant:** This means the cancer does not respond well to chemotherapy that uses drugs containing platinum.
- **RECIST v1.1:** A set of rules to measure if the cancer is shrinking, staying the same, or growing.
- **ECOG performance status:** A scale to measure how cancer impacts a person's daily living abilities.
Key Points:
- Participants must be female, 18 or older, and have a specific type of ovarian cancer.
- Women need to agree not to get pregnant and not to breastfeed during and after the study.
- The study will have certain medical check-ups to ensure participants' safety.
How understandable was the trial content above?
Hard to understand
Easy to understand